Article
 

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Público Deposited

Contenido Descargable

Descargar PDF
https://ir.library.oregonstate.edu/concern/articles/cf95jd15r

Descriptions

Attribute NameValues
Creator
Abstract
  • Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to 2013. We compared changes in DMT costs to general and prescription drug inflation during the same period. We also compared the cost trajectories for first-generation MS DMTs interferon (IFN)–β-1b, IFN-β-1a IM, and glatiramer acetate with contemporaneously approved biologic tumor necrosis factor (TNF) inhibitors. Results: First-generation DMTs, originally costing $8,000 to $11,000, now cost about $60,000 per year. Costs for these agents have increased annually at rates 5 to 7 times higher than prescription drug inflation. Newer DMTs commonly entered the market with a cost 25%–60% higher than existing DMTs. Significant increases in the cost trajectory of the first-generation DMTs occurred following the Food and Drug Administration approvals of IFN-β-1a SC (2002) and natalizumab (reintroduced 2006) and remained high following introduction of fingolimod (2010). Similar changes did not occur with TNF inhibitor biologics during these time intervals. DMT costs in the United States currently are 2 to 3 times higher than in other comparable countries. Conclusions: MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs.
  • CORRECTIONS: In the article “The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?” by D.M. Hartung et al. (Neurology® 2015;84:2185–2192), there is an error in table 1. Columns 5–7 should have been labeled “cumulative percent change per year” rather than “annualized changes.” The authors regret the error. Correction is attached as a separate pdf. This is the publisher’s final pdf. The article is published by Lippincott, Williams & Wilkins and copyrighted by American Academy of Neurology. The published article can be found at: http://www.neurology.org/
Resource Type
DOI
Fecha Disponible
Fecha de Emisión
Citation
  • Hartung, D. M., Bourdette, D. N., Ahmed, S. M., & Whitham, R. H. (2015). The cost of multiple sclerosis drugs in the US and the pharmaceutical industry Too big to fail?. Neurology, 84(21), 2185-2192. doi:10.1212/WNL.0000000000001608
Journal Title
Journal Volume
  • 84
Journal Issue/Number
  • 21
Declaración de derechos
Funding Statement (additional comments about funding)
  • D. Bourdette has served as a consultant for Teva Neurosciences and Biogen Idec and has had research grants from the Department of Veterans Affairs, National MS Society, and NIH. S. Ahmed reports no disclosures relevant to the manuscript. R. Whitham reports serving on the Independent Data Monitoring Committee for a clinical trial sponsored by Chugai Pharmaceutical Co.
Publisher
Peer Reviewed
Language
Replaces

Relaciones

Parents:

This work has no parents.

Elementos

Miniatura Título Fecha de subida Visibilidad Acciones
file details HartungDanielPharmacyCostMulitpleSclerosis.pdf 07/26/2017 Público
file details HartungDanielPharmacyCostMulitpleSclerosis(Correction).pdf 07/26/2017 Público
file details HartungDanielPharmacyCostMulitpleSclerosisSupplementaryAppendix.pdf 07/26/2017 Público
file details HartungDanielPharmacyCostMulitpleSclerosis(Podcast).mp3 07/26/2017 Público